La monoterapia con EBGLYSS alcanzó su criterio de valoración principal: más de la mitad de los pacientes lograron una piel clara o casi clara en las manos y los pies (HF-IGA 0/1) por semana...

Las acciones de Eli Lilly and Company estaban a 1043,40 EUR en Lang & Schwarz el 30 de septiembre de 2026, más 0,23 pe

Investing.com -- Shares of Eli Lilly and Company (NYSE: LLY) climbed as much as 2.6% before settling up 0.5% after the pharmaceutical giant reported highly positive Phase 2b trial results for its new obesity and type 2 diabetes drug combination. As Lilly’s stock advanced, shares of primary competitor Novo Nordisk slipped 0.3% on the news.

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial...

South Korea expands insurance to cover three cancer drugs and first combo Coverage widens from October for Retsevmo, Vyloy, and the Padcev–Keytruda first-line combo to ease cancer patients costs

Eli Lilly (NYSE: LLY) received FDA Breakthrough Therapy designation for olomorasib in advanced pancreatic cancer, according to a recent company update. The designation covers olomorasib, a KRAS G12C inhibitor, intended for patients with advanced pancreatic tumors who have limited treatment options. Chief executive David Ricks has signaled interest in larger acquisitions across areas such as infectious disease, women’s health and psychiatric conditions. The Breakthrough Therapy status for...

Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Eli Lilly CEO Dave Ricks said at a diabetes conference in Milan that investors should expect the drugmaker to pursue larger acquisitions as it hunts…

Un ejecutivo de recursos humanos comparte su opinión sobre la gestión de la cultura y la experiencia de los empleados durante el rápido crecimiento organizacional.